Multivalent Meningiococcal Conjugates and Methods for Preparing Conjugates
Download the Abstract (PDF - 88KB)
Technology Summary
Among 13 isolated meningococcal serogroups, A, B, C, W-135 and Y are the most prevalent. There are three FDA-approved capsular polysaccharide (PS)-based vaccines, one tetravalent PS vaccine, and two tetravalent conjugate vaccines for protection against meningococcal disease caused by groups A, C, W-135 and Y Neisseria meningitidis. However, there is no (PS)-based vaccine for Group B capsular PS. There is a genuine need to develop novel meningococcal vaccines, particularly for group B and group X meningococcal serogroups.
FDA inventors developed a modified CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) conjugation method where meningococcal factor H binding protein (fHbp) conjugates with groups A, C, W-135 and PS. The resulting conjugates serve as effective carriers for PS in mice. The induced antisera are bactericidal against both serogroups A, C, W-135 and Y AND serogroup B. Further, the antisera are bactericidal for serogroup X strains that that express fHbp1 on its surface.
| Potential Commercial Applications | Competitive Advantages |
|---|---|
|
|
Inventors: Che-Hung Robert Lee, Vavlerian Pinto
Publications:
Pinto VB, Burden R, Wagner A, Moran EE, Lee CH. The development of an experimental multiple serogroups vaccine for Neisseria meningitidis. PLoS One. 2013;8(11):e79304. PMID: 24244473
Intellectual Property: United States Patent No. US 9,427,476 issued 08.30.2016
Product Area: Vaccine, multivalent vaccine, CDAP conjugation
FDA Reference No: E-2012-005
Licensing Contact:
Ken Millburne, J.D.
FDA Technology Transfer Program
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 301-346-3964